83 related articles for article (PubMed ID: 7996464)
1. Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids.
Yodoya E; Uemura K; Tenma T; Fujita T; Murakami M; Yamamoto A; Muranishi S
J Pharmacol Exp Ther; 1994 Dec; 271(3):1509-13. PubMed ID: 7996464
[TBL] [Abstract][Full Text] [Related]
2. [Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids].
Yamamoto A
Nihon Rinsho; 1998 Mar; 56(3):601-7. PubMed ID: 9549343
[TBL] [Abstract][Full Text] [Related]
3. Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats.
Tenma T; Yodoya E; Tashima S; Fujita T; Murakami M; Yamamoto A; Muranishi S
Pharm Res; 1993 Oct; 10(10):1488-92. PubMed ID: 8272412
[TBL] [Abstract][Full Text] [Related]
4. Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors.
Fujita T; Kawahara I; Quan Y; Hattori K; Takenaka K; Muranishi S; Yamamoto A
Pharm Res; 1998 Sep; 15(9):1387-92. PubMed ID: 9755890
[TBL] [Abstract][Full Text] [Related]
5. Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids.
Setoh K; Murakami M; Araki N; Fujita T; Yamamoto A; Muranishi S
J Pharm Pharmacol; 1995 Oct; 47(10):808-11. PubMed ID: 8583347
[TBL] [Abstract][Full Text] [Related]
6. Enhanced transdermal delivery of phenylalanyl-glycine by chemical modification with various fatty acids.
Yamamoto A; Setoh K; Murakami M; Shironoshita M; Kobayashi T; Fujimoto K; Okada N; Fujita T; Muranishi S
Int J Pharm; 2003 Jan; 250(1):119-28. PubMed ID: 12480278
[TBL] [Abstract][Full Text] [Related]
7. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine.
Asada H; Douen T; Waki M; Adachi S; Fujita T; Yamamoto A; Muranishi S
J Pharm Sci; 1995 Jun; 84(6):682-7. PubMed ID: 7562404
[TBL] [Abstract][Full Text] [Related]
8. Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.
Uchiyama T; Kotani A; Tatsumi H; Kishida T; Okamoto A; Okada N; Murakami M; Fujita T; Fujiwara Y; Kiso Y; Muranishi S; Yamamoto A
Pharm Res; 2000 Dec; 17(12):1461-7. PubMed ID: 11303954
[TBL] [Abstract][Full Text] [Related]
9. Enhanced permeability of phenylalanyl-glycine (Phe-Gly) across the intestinal membranes by chemical modification with various fatty acids.
Yamamoto A; Morishita Y; Sugishita S; Hayami T; Okada N; Fujita T; Muranishi S
Drug Metab Pharmacokinet; 2003; 18(1):23-32. PubMed ID: 15618716
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent bile acid derivatives: relationship between chemical structure and hepatic and intestinal transport in the rat.
Holzinger F; Schteingart CD; Ton-Nu HT; Eming SA; Monte MJ; Hagey LR; Hofmann AF
Hepatology; 1997 Nov; 26(5):1263-71. PubMed ID: 9362371
[TBL] [Abstract][Full Text] [Related]
11. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat.
Dahan A; West BT; Amidon GL
Eur J Pharm Sci; 2009 Feb; 36(2-3):320-9. PubMed ID: 19028572
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes.
Velkov T
Mol Pharm; 2009; 6(2):557-70. PubMed ID: 19265444
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of intestinal absorption and metabolism of promising anti-Alzheimer's dimer bis(7)-tacrine.
Zhang L; Yu H; Li WM; Cheung MC; Pang YP; Gu ZM; Chan K; Wang YT; Zuo Z; Han YF
Int J Pharm; 2008 Jun; 357(1-2):85-94. PubMed ID: 18358649
[TBL] [Abstract][Full Text] [Related]
14. Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats.
Atkinson LL; Kozak R; Kelly SE; Onay Besikci A; Russell JC; Lopaschuk GD
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E923-30. PubMed ID: 12464581
[TBL] [Abstract][Full Text] [Related]
15. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):884-93. PubMed ID: 16226752
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
[TBL] [Abstract][Full Text] [Related]
17. Intestinal metabolism and absorption of cholecystokinin analogs in rats.
Su SF; Amidon GL; Lee HJ
Biochem Biophys Res Commun; 2002 Apr; 292(3):632-8. PubMed ID: 11922613
[TBL] [Abstract][Full Text] [Related]
18. An in vitro evaluation of metabolism and poor membrane permeation impeding intestinal absorption of leucine enkephalin, and methods to increase absorption.
Aungst BJ; Blake JA; Hussain MA
J Pharmacol Exp Ther; 1991 Oct; 259(1):139-45. PubMed ID: 1920113
[TBL] [Abstract][Full Text] [Related]
19. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats.
Kim J; Han KS; Lee JW; Lee MG
Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504
[TBL] [Abstract][Full Text] [Related]
20. Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat.
Batta AK; Xu G; Honda A; Miyazaki T; Salen G
Metabolism; 2006 Mar; 55(3):292-9. PubMed ID: 16483871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
